← feed

Is NCT01363817 results overdue?

Yes — results are overdue. Primary completion was 2018-02-07; the FDAAA-801 reporting deadline (2019-02-07) passed 2737 days ago and no results are posted on ClinicalTrials.gov.

Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

NCT IDNCT01363817 ↗
SponsorBristol-Myers Squibb (INDUSTRY)
Public issuerBRISTOL MYERS SQUIBB CO — BMY (CIK 0000014272) best-effort name match, 95% conf — verify on EDGAR ↗
PhasePHASE1
StatusCOMPLETED
Primary completion2018-02-07 (ACTUAL)
Reporting deadline2019-02-07 (completion + 365d)
Days overdue2737
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 1930110982ec0e77… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT01363817. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →